Fig 1.
Total CD4+ T cell proliferation rates estimated from D2-glucose and D2O labeling studies in humans.
Each symbol represents a different individual, horizontal lines represent the median of the estimates. (A) Proliferation rates estimated using the kinetic heterogeneity model. (B) Proliferation rates estimated after adjusting for saturation (using the multi-exponential model for the nine-week (9w) D2O and seven-day (7d) D2-glucose labeling, and the kinetic heterogeneity model for one-day (1d) D2-glucose labeling). Although correcting for the saturation of rapidly turning over subpopulations helps to bring the estimates closer (by increasing the proliferation rate estimates obtained in the nine-week D2O labeling study) significant discrepancies remain.
Fig 2.
Proliferation rates of Jurkat cells growing in vitro estimated using D2-glucose and D2O labeling.
Each symbol represents the proliferation rate estimated in a separate experiment, horizontal lines represent the median of the estimated proliferation rates.
Fig 3.
Enrichment curves of D2-glucose labeled mice.
Best fits to the fraction of deuterium enrichment in plasma, and the percentage of label enrichment in the DNA of PBMC, splenocytes and thymocytes after seven-days of D2-glucose labeling. Dots represent individual mice. The end of label administration at day 7 is marked by a dashed vertical line. (A) Conventional normalization: measurements are normalized to the mean plasma enrichment x bg. (B) Normalized with respect to thymocytes: thymocytes were used to determine the maximum percentage of labeled DNA that cells could possibly attain (Methods), and all measured enrichments were scaled to this maximum. The raw data of the % DNA labeled in splenocytes and PBMC is the same in panel A and B but has been normalized using two different approaches.
Fig 4.
Enrichment curves of D2O labeled mice.
Best fits to the fraction of deuterium enrichment in plasma (A) and the percentage of label enrichment in the DNA of thymocytes (B), PBMC (C), and splenocytes (D) after seven-days of D2O labeling. Thymocytes were used to determine the maximum percentage of labeled DNA that cells could possibly attain (Methods), and all measured enrichments were scaled to this maximum. Dots represent individual mice. The end of label administration at day 7 is marked by a dashed vertical line.
Fig 5.
Proliferation rate estimates from 1 week D2-glucose and D2O labeling in mice.
The average proliferation rate of PBMC and splenocytes, obtained by fitting the kinetic heterogenity model to the data collected during labeling with D2-glucose with conventional normalization (using 0.65 × plasma AUC, filled circles), labeling with D2-glucose with normalization to thymocytes (grey-filled circles) and labeling with D2O with conventional normalization i.e. to thymocytes (open circles). Bars represent 95% confidence intervals; AUC = area under the curve.
Fig 6.
Impact of light-dark cycle on plasma glucose enrichment in mice.
The fraction of deuterium enrichment of plasma glucose is plotted against time since the start of label modulo 24 h. Data from mice housed under reversed day/night condition is translated by 12h so that for all mice 0h represents the start of light phase (8am for normal conditions, 8pm for reversed day/night conditions). Grey circles represent measurements from individual mice, the line connects the medians, the points plotted at 24h/0h are duplicates of the 0h data.
Fig 7.
Deuterium enrichment in plasma glucose in one-day and seven-day D2-glucose labeling studies of humans.
The measured enrichment in plasma glucose in the one-day (grey circles) and seven-day (black diamonds) D2-glucose labeling studies. The end of the one-day and seven-day labeling periods are marked by a dashed grey line and a dotted black line respectively. Although subjects in the one-day labeling experiment (N = 8) received approximately twice as much deuterated glucose per day as subjects in the seven-day labeling study (N = 4), their median label enrichment is only slightly higher. Median plasma glucose enrichment in the one-day labeling study = 23%, median plasma glucose enrichment in the seven-day labeling study = 17%.
Table 1.
Estimates of the plateau enrichment of monocytes in humans.
Fig 8.
Model of monocyte development.
Monocyte progenitors in the bone marrow (M(t)) proliferate at rate p, transit into a maturation compartment at rate ε, where they mature for a fixed time (Δ) before exiting into the blood compartment (B(t)), from which they disappear at rate d.